Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies


Anti-GD2 immunotherapy

Some children with high-risk neuroblastoma are eligible for anti-GD2 immunotherapy with dinutuximab. This treatment prompts the immune system to eliminate tumor cells.

Ordinarily, our immune system destroys foreign and abnormal cells. But neuroblastoma cells are difficult for the immune system to recognize. Your child is therefore given dinutuximab, a GD-2 antibody (anti-GD2).

Dinutuximab binds to GD-2, which sits on the surface of neuroblastoma cells. This sends a signal to the immune system that foreign cells have been identified. The immune system kicks in and destroys these foreign cells (the neuroblastoma cells).

Dinutuximab treatment starts after high dose chemotherapy with autologous stem cell transplantation and continues for approximately six months. Part of the treatment can be administered at home.

All information about this treatment can be found in the brochure Anti-GD2 immunotherapy (only in Dutch).

The department enters your child’s treatment details in the brochure Dinutuximab at home for you to take home.

Should you need any further information, please feel free to ask.